Supporting our global approach to clinical development and market supply, we recently completed the build of a 29,000-square foot cGMP manufacturing facility located in London. The facility was designed to meet multiple regulatory standards, including the Medicines and Health Products Regulatory Agency (MHRA), in the UK, European Medicine Agency (EMA) and U.S. Food and Drug Administration (FDA) standards.
Our manufacturing team consists of more than 30 highly trained multidisciplinary staff with backgrounds in manufacturing, managing and delivering gene therapy products.
“Gene therapy is a next-generation medicine that requires novel manufacturing technologies in order to be both flexible and scalable. Flexibility allows us to take our process and apply it to new medicines and address markets that we previously would not have been able. The efficiency and simplified scale-up allow for shorter production time and increases our ability to potentially help a greater number of patients.”
– Stuart Naylor, Ph.D., Chief Development Officer